US Patent Issued to Allogene Therapeutics on March 17 for "FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death" (California Inventors)

ALEXANDRIA, Va., March 17 -- United States Patent no. 12,577,290, issued on March 17, was assigned to Allogene Therapeutics Inc. (South San Francisco, Calif.).

"FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death" was invented by Michael Thomas Bethune (Castro Valley, Calif.), Eric Hans Gschweng (Oak Park, Calif.), Thomas John Van Blarcom (Oakland, Calif.) and Cesar Adolfo Sommer (San Mateo, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compositions, methods, expression vectors and engineered immune cells for improving therapies that entail the administration of allogeneic cells to a patient. An immune cell, e.g., a T cell, m...